spironolactone has been researched along with Anxiety in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d)." | 9.04 | [Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)]. ( Ebel, H; Klaus, D; Lübke, H; Witzgall, H; Zehner, J, 1978) |
| "Single injection of eplerenone is followed by a reduction of ethological indices of anxiety-like behaviour and by an elevation of plasma aldosterone levels." | 7.74 | Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. ( Hlavacova, N; Jezova, D, 2008) |
| "In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d)." | 5.04 | [Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)]. ( Ebel, H; Klaus, D; Lübke, H; Witzgall, H; Zehner, J, 1978) |
| "Single injection of eplerenone is followed by a reduction of ethological indices of anxiety-like behaviour and by an elevation of plasma aldosterone levels." | 3.74 | Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. ( Hlavacova, N; Jezova, D, 2008) |
| "The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus." | 3.70 | Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. ( Bitran, D; Dowd, JA; Dugan, MM; Renda, P; Shiekh, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| de Azevedo Camin, N | 1 |
| Traslaviña, GAA | 1 |
| de Barcellos Filho, PCG | 1 |
| Franci, CR | 1 |
| Karailiev, P | 1 |
| Hlavacova, N | 2 |
| Chmelova, M | 1 |
| Homer, NZM | 1 |
| Jezova, D | 2 |
| López-Rubalcava, C | 1 |
| Paez-Martinez, N | 1 |
| Oikawa, J | 1 |
| Xu, C | 1 |
| Tan, S | 1 |
| Zhang, J | 1 |
| Seubert, CN | 1 |
| Gravenstein, N | 1 |
| Sumners, C | 1 |
| Vasilopoulos, T | 1 |
| Martynyuk, AE | 1 |
| Fox, LC | 1 |
| Davies, DR | 1 |
| Scholl, JL | 1 |
| Watt, MJ | 1 |
| Forster, GL | 1 |
| Myers, B | 1 |
| Greenwood-Van Meerveld, B | 1 |
| Korte, SM | 2 |
| de Boer, SF | 1 |
| de Kloet, ER | 2 |
| Bohus, B | 2 |
| Korte-Bouws, GA | 1 |
| Koob, GF | 1 |
| Smythe, JW | 1 |
| Murphy, D | 1 |
| Timothy, C | 1 |
| Costall, B | 1 |
| Bitran, D | 1 |
| Shiekh, M | 1 |
| Dowd, JA | 1 |
| Dugan, MM | 1 |
| Renda, P | 1 |
| Calvo, N | 1 |
| Volosin, M | 1 |
| Ebel, H | 1 |
| Lübke, H | 1 |
| Klaus, D | 1 |
| Zehner, J | 1 |
| Witzgall, H | 1 |
| Demers, RG | 1 |
| Hendler, R | 1 |
| Allen, RP | 1 |
| Boyd, J | 1 |
1 trial available for spironolactone and Anxiety
| Article | Year |
|---|---|
[Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].
Topics: Anxiety; Bradycardia; Dihydralazine; Drug Therapy, Combination; Female; Humans; Hydralazine; Hydroch | 1978 |
13 other studies available for spironolactone and Anxiety
| Article | Year |
|---|---|
Early post-stress administration of MR or GR antagonist in adolescent female rats restored anxiogenic-like behavior and modified the HPA axis response in the adulthood.
Topics: Animals; Anxiety; Corticosterone; Corticotropin-Releasing Hormone; Female; Glucocorticoids; Hypothal | 2022 |
Tight junction proteins in the small intestine and prefrontal cortex of female rats exposed to stress of chronic isolation starting early in life.
Topics: Animals; Anxiety; Claudin-5; Female; Intestine, Small; Mineralocorticoid Receptor Antagonists; Occlu | 2021 |
Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Blood Glucose; Diabetes Mellitus, Experimental; Diazepam; Dos | 2013 |
Anesthesia with sevoflurane in neonatal rats: Developmental neuroendocrine abnormalities and alleviating effects of the corticosteroid and Cl(-) importer antagonists.
Topics: Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Animals, Newborn; Anxiety; Bumetanide; CA1 | 2015 |
Differential effects of glucocorticoid and mineralocorticoid antagonism on anxiety behavior in mild traumatic brain injury.
Topics: Animals; Anxiety; Brain Concussion; Male; Mifepristone; Mineralocorticoid Receptor Antagonists; Rats | 2016 |
Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Antihypertensive Agents; Anxiety; Behavior, Anima | 2008 |
Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Catheterization; Colon; Drug Implants; Hormone Antagon | 2007 |
Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze.
Topics: Animals; Anxiety; Behavior, Animal; Fear; Injections, Intraventricular; Male; Maze Learning; Mifepri | 1995 |
Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety.
Topics: Acoustic Stimulation; Animals; Anxiety; Behavior, Animal; Electroshock; Fear; Hormone Antagonists; I | 1996 |
Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats.
Topics: Analysis of Variance; Animals; Anxiety; Drug Evaluation, Preclinical; Hippocampus; Male; Microinject | 1997 |
Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors.
Topics: Adrenalectomy; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Anxiety; Corticosterone; Cort | 1998 |
Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint.
Topics: Adrenalectomy; Animals; Anti-Inflammatory Agents; Anxiety; Corticosterone; Dexamethasone; Injections | 2001 |
Edema and increased plasma renin activity in lithium treated patients.
Topics: Adult; Affective Symptoms; Aldosterone; Anxiety; Bipolar Disorder; Carbonates; Chlorpromazine; Diet; | 1971 |